Readystate Asset Management LP Decreases Stock Holdings in Krystal Biotech, Inc. $KRYS

Readystate Asset Management LP reduced its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 52.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 70,349 shares of the company’s stock after selling 77,631 shares during the period. Readystate Asset Management LP’s holdings in Krystal Biotech were worth $12,419,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Royal Bank of Canada boosted its stake in Krystal Biotech by 145.2% during the first quarter. Royal Bank of Canada now owns 1,628 shares of the company’s stock worth $294,000 after buying an additional 964 shares during the last quarter. AQR Capital Management LLC raised its holdings in shares of Krystal Biotech by 29.9% during the 1st quarter. AQR Capital Management LLC now owns 12,131 shares of the company’s stock worth $2,187,000 after acquiring an additional 2,792 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Krystal Biotech by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,893 shares of the company’s stock valued at $2,870,000 after acquiring an additional 688 shares during the last quarter. Empowered Funds LLC acquired a new position in shares of Krystal Biotech during the 1st quarter valued at about $218,000. Finally, CWM LLC grew its holdings in shares of Krystal Biotech by 7.2% in the second quarter. CWM LLC now owns 1,583 shares of the company’s stock valued at $218,000 after purchasing an additional 107 shares during the period. Institutional investors and hedge funds own 86.29% of the company’s stock.

Insider Buying and Selling

In other news, CAO Kathryn Romano sold 12,500 shares of the company’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $272.14, for a total transaction of $3,401,750.00. Following the sale, the chief accounting officer owned 19,318 shares of the company’s stock, valued at approximately $5,257,200.52. This represents a 39.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $220.16, for a total value of $5,504,000.00. Following the completion of the sale, the insider owned 1,413,711 shares in the company, valued at approximately $311,242,613.76. The trade was a 1.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 13.70% of the stock is owned by corporate insiders.

Key Krystal Biotech News

Here are the key news stories impacting Krystal Biotech this week:

• Positive Sentiment: Q4 revenue and EPS beat — VYJUVEK net product revenue of $107.1M (Q4) and $389.1M (FY), and EPS that topped estimates, supporting higher near‑term profitability. Krystal Biotech Announces Q4 and FY2025 Results
• Positive Sentiment: Regulatory designations accelerate development: FDA granted RMAT to KB707 (advanced NSCLC) and Fast Track to KB111 (Hailey‑Hailey disease), which can speed review and regulatory interactions. Quiver: 4Q Revenue & FDA Designations
• Positive Sentiment: Strong balance sheet — ~$956M in cash and investments at year‑end provides runway for multiple trials and commercialization efforts. Quiver: Cash Position
• Neutral Sentiment: Positive clinical signals in respiratory programs (KB407 cystic fibrosis cohort showed lung delivery/expression; CORAL‑3 repeat‑dose study discussions with FDA planned), supporting longer‑term upside but still early stage. GlobeNewswire: Pipeline Updates
• Negative Sentiment: The company raised FY‑2026 non‑GAAP combined R&D & SG&A guidance but did not provide a GAAP reconciliation because it cannot confidently estimate stock‑based comp — this increases uncertainty about true GAAP expense and margins. GlobeNewswire: Guidance Note
• Negative Sentiment: Rising operating costs — SG&A increased year‑over‑year (notably stock‑based comp), which could pressure operating leverage as commercialization expands. GlobeNewswire: Expense Details
• Negative Sentiment: European rollout timing risk — pricing negotiations in Germany and France could delay broader European revenue; reimbursement timelines extend into 2026–2027. Quiver: Europe Pricing Risk
• Neutral Sentiment: Investor materials and earnings call transcript provide more color on commercial cadence and trial timelines — useful for due diligence. Seeking Alpha: Earnings Call Transcript

Krystal Biotech Trading Up 4.1%

KRYS opened at $287.84 on Wednesday. The stock’s 50-day moving average price is $263.97 and its 200 day moving average price is $207.87. Krystal Biotech, Inc. has a 12-month low of $122.80 and a 12-month high of $298.30. The firm has a market cap of $8.35 billion, a price-to-earnings ratio of 43.15 and a beta of 0.49.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Tuesday, February 17th. The company reported $1.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. Krystal Biotech had a net margin of 53.30% and a return on equity of 19.36%. The company had revenue of $107.11 million for the quarter, compared to analyst estimates of $105.30 million. On average, research analysts forecast that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Zacks Research downgraded shares of Krystal Biotech from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 5th. TD Cowen restated a “buy” rating on shares of Krystal Biotech in a report on Friday, January 9th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Krystal Biotech in a report on Monday, December 29th. Chardan Capital raised their target price on Krystal Biotech from $216.00 to $220.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. Finally, HC Wainwright restated a “buy” rating and issued a $310.00 target price (up previously from $240.00) on shares of Krystal Biotech in a research report on Friday, January 9th. Nine analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, Krystal Biotech currently has an average rating of “Moderate Buy” and a consensus price target of $291.89.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.